Vanda Pharmaceuticals (VNDA) EBITDA (2010 - 2026)

Vanda Pharmaceuticals has reported EBITDA for 17 years, with the latest figure at -$50.2 million in Q1 2026.

• Quarterly EBITDA fell 22.41% year-over-year to -$50.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$160.4 million (down 121.34% YoY) and the FY2025 annual result came in at -$151.2 million, down 271.79% from the prior year.
• EBITDA fell to -$50.2 million in Q1 2026 per VNDA's latest filing, from -$40.4 million in the prior quarter.
• Over five years, EBITDA peaked at $6.6 million in Q4 2022 and troughed at -$50.2 million in Q1 2026.
• A 5-year average of -$14.7 million and a median of -$9.2 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2023 and 2024: EBITDA soared 126.13% in 2023, then tumbled 560.83% in 2024.
• Over 5 years, EBITDA stood at $6.6 million in 2022, then tumbled by 207.01% to -$7.1 million in 2023, then plunged by 44.9% to -$10.3 million in 2024, then plunged by 292.58% to -$40.4 million in 2025, then dropped by 24.46% to -$50.2 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$50.2 million, -$40.4 million, and -$31.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.